Locoregional therapy

PROCEDURE2 trials

Sponsors

Chen Xiaoping, Sun Yat-sen University

Conditions

Advanced Hepatocellular CarcinomaAnti-PD1/PDL1 AntibodyBevacizumabHepatocellular Carcinoma

Unknown Phase

Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.

Active, not recruitingNCT06248528

Chen XiaopingHepatocellular Carcinoma

Start: 2019-12-01End: 2027-01-31Updated: 2025-07-16

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

RecruitingNCT06323382

Sun Yat-sen UniversityAdvanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab

Start: 2021-01-01End: 2025-12-30Target: 240Updated: 2025-08-14